{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"ADA prevalence (i.e., ADA positive) at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"ADA-positive participants on-treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"}],"units":"Participants"}],"description":"Anti-drug Antibody (ADA) prevalence is the number of participants with at least one sample meeting the criteria at baseline. ADA-positive participants were calculated as the number of participants with at least one on-treatment ADA-positive sample divided by the number of participants with a determinant baseline IG sample and at least one determinant post-baseline IG sample.","groups":[{"description":"Participants received sabatolimab","id":"OG000","title":"Sabatolimab (MBG453)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity Incidence Set includes all participants in the Immunogenicity prevalence set with a non-missing baseline ADA sample and at least one non-missing post-baseline ADA sample.\n\nThe Immunogenicity prevalence set includes all participants in the Safety Set with a non-missing baseline ADA sample or at least one non-missing post-baseline ADA sample.","reportingStatus":"POSTED","timeFrame":"Baseline, up to approx. 39 months","title":"ADA Prevalence at Baseline and ADA-positive Participants On-treatment","type":"SECONDARY","unitOfMeasure":"Participants"}